Oculis (OCS) Competitors $18.27 +0.08 (+0.41%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. HCM, KYMR, CRNX, IMVT, ALVO, MOR, OGN, NAMS, RXRX, and GMTXShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include HUTCHMED (HCM), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Alvotech (ALVO), MorphoSys (MOR), Organon & Co. (OGN), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors HUTCHMED Kymera Therapeutics Crinetics Pharmaceuticals Immunovant Alvotech MorphoSys Organon & Co. NewAmsterdam Pharma Recursion Pharmaceuticals Gemini Therapeutics HUTCHMED (NASDAQ:HCM) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do analysts rate HCM or OCS? HUTCHMED presently has a consensus price target of $28.00, suggesting a potential upside of 86.59%. Oculis has a consensus price target of $35.33, suggesting a potential upside of 93.34%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in HCM or OCS? 8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, HCM or OCS? HUTCHMED has higher revenue and earnings than Oculis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M4.15$37.73MN/AN/AOculisN/AN/A-$97.43M-$2.64-6.92 Is HCM or OCS more profitable? HUTCHMED has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. HUTCHMED's return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Oculis -13,788.70%-92.95%-70.03% Does the media refer more to HCM or OCS? In the previous week, HUTCHMED and HUTCHMED both had 1 articles in the media. Oculis' average media sentiment score of 0.83 beat HUTCHMED's score of 0.00 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, HCM or OCS? HUTCHMED has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. SummaryHUTCHMED beats Oculis on 7 of the 12 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$797.88M$2.98B$5.44B$9.65BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-6.9218.0530.0425.06Price / SalesN/A175.18373.4277.08Price / CashN/A41.8335.9458.58Price / Book9.577.218.125.67Net Income-$97.43M-$54.43M$3.25B$265.39M7 Day Performance3.25%0.07%0.96%2.54%1 Month Performance-1.96%5.29%2.69%1.89%1 Year Performance56.87%9.94%28.08%24.09% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis3.0289 of 5 stars$18.28+0.4%$35.33+93.3%+57.6%$797.88MN/A-6.922Positive NewsHCMHUTCHMED2.6435 of 5 stars$17.98+2.1%$23.50+30.7%-16.9%$3.07B$630.20M0.001,811News CoverageGap DownKYMRKymera Therapeutics3.4593 of 5 stars$44.20-3.5%$59.11+33.7%+1.3%$2.98B$58.89M-14.26170Upcoming EarningsCRNXCrinetics Pharmaceuticals3.322 of 5 stars$30.30-2.2%$69.50+129.4%-42.3%$2.90B$760K-7.93210Earnings ReportIMVTImmunovant1.5403 of 5 stars$16.76-1.1%$36.40+117.2%-41.7%$2.90BN/A-6.12120Positive NewsALVOAlvotech2.8588 of 5 stars$9.81+2.1%$14.00+42.7%-23.3%$2.90B$491.98M26.511,032MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730OGNOrganon & Co.4.8395 of 5 stars$9.96-2.4%$18.00+80.7%-52.2%$2.65B$6.40B3.464,000Earnings ReportDividend AnnouncementNAMSNewAmsterdam Pharma3.583 of 5 stars$23.42-0.8%$41.30+76.3%+46.6%$2.65B$45.56M-12.464News CoveragePositive NewsEarnings ReportAnalyst ForecastRXRXRecursion Pharmaceuticals1.8745 of 5 stars$6.31-2.8%$7.00+10.9%-15.1%$2.64B$58.84M-3.56400Earnings ReportAnalyst RevisionGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+40.1%$2.63BN/A-60.6130Gap Down Related Companies and Tools Related Companies HCM Competitors KYMR Competitors CRNX Competitors IMVT Competitors ALVO Competitors MOR Competitors OGN Competitors NAMS Competitors RXRX Competitors GMTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
